| 主权项 |
1. A method for treating a subject having a refractory obsessive compulsive disorder (OCD), the method comprising:
administering to the subject a therapeutic amount of a composition for a continuous period of 3 months, 6 months, 6.5 months, 1 year, or 4.5 years, comprising:
(i) an agonist of at least one N-methyl-D-aspartate receptor (NMDAR) having the structure: wherein R1 or R2 is —H, —CH3, —C1-C6 alkyl, —C2-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, -aryl, —(C1-C6 alkyl)-aryl, —C3-C6 alkyl, C2-C4 alkyl, —OR5, —CN, —CF3, —OCF3, —NO2, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)—(C1-C6 alkyl), —NHC(O)NH(C1-C6 alkyl), —SO2NH2, —SO2NH(C1-C6 alkyl), —SO2N(C1-C6 alkyl)2, —NHSO(C1-C6 alkyl), —C(O)O—(C1-C6 alkyl), —C(O)NH(C1-C6 alkyl), or —C(O)N(C1-C6 alkyl)2;R3 or R4 is —H, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, -aryl, —CH2—O—R5, —CH2—R5, —(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle or —(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle), wherein the —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, -aryl, —(C1-C6 alkyl)-aryl, -5 or 6-membered aromatic or non-aromatic heterocycle or —(C1-C6 alkyl)-(5 or 6-membered aromatic or non-aromatic heterocycle) group is unsubstituted or substituted with at least one of the following groups: -halo, —OR5, —CN, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, —CF3, —OCF3, —NO2, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, —NHC(O)—(C1-C6 alkyl), —NHC(O)NH(C1-C6 alkyl), —SO2NH2, —SO2NH(C1-C6 alkyl), —SO2N(C1-C6 alkyl)2, —NHSO(C1-C6 alkyl), —C(O)O—(C1-C6 alkyl), —C(O)NH(C1-C6 alkyl), or —C(O)N(C1-C6 alkyl)2;Y is -halo, —OR5, —CN, —C1-C6 alkyl, —C2-C6 alkenyl, —C2-C6 alkynyl, -aryl, —(C1-C6 alkyl)-aryl, —CF3, —OCF3, —NO2, —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2, or —NHNH—R5; andR5=R1 or R3;whereinthe agonist of the at least one N-methyl-D-aspartate receptor (NMDAR) is glycine or a derivative thereof; and(ii) a carrier;whereinthe therapeutic amount is effective to reduce at least one obsessive-compulsive disorder (OCD) behavior by the subject relative to a control subject who has not been treated with the composition, andthe obsessive-compulsive disorder (OCD) behavior is selected from the group consisting of a social discomfort behavior, a mirror intolerance behavior, a perseverative behavior, a line-crossing obsession, a prayer ritual, a hand washing ritual, or a combination thereof; andadministering a therapeutic amount of L-arginine to the subject, wherein the therapeutic amount of arginine is effective to treat hyperammonemia without increasing inflammation. |
